https://www.biospace.com/all-news All News en-US Thu, 04 Jun 2026 15:37:08 GMT https://www.biospace.com/job-trends/massachusetts-life-sciences-employment-dipped-last-year-following-14-years-of-growth-report Angela Gabriel Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists. Thu, 04 Jun 2026 15:37:08 GMT https://www.biospace.com/job-trends/massachusetts-life-sciences-employment-dipped-last-year-following-14-years-of-growth-report https://www.biospace.com/business/lilly-and-boehringer-roll-back-billions-in-german-investments-over-health-budget-cuts Nick Paul Taylor With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. Thu, 04 Jun 2026 14:05:11 GMT https://www.biospace.com/business/lilly-and-boehringer-roll-back-billions-in-german-investments-over-health-budget-cuts https://www.biospace.com/business/peptide-biotech-parabilis-targets-up-to-476m-ipo Gabrielle Masson Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing. Thu, 04 Jun 2026 13:48:45 GMT https://www.biospace.com/business/peptide-biotech-parabilis-targets-up-to-476m-ipo https://www.biospace.com/drug-development/adc-therapeutics-nosedives-on-27-deaths-in-confirmatory-trial-for-lymphoma-drug Tristan Manalac In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication. Thu, 04 Jun 2026 13:08:23 GMT https://www.biospace.com/drug-development/adc-therapeutics-nosedives-on-27-deaths-in-confirmatory-trial-for-lymphoma-drug https://www.biospace.com/deals/regeneron-deepens-relationship-with-cytomx-adding-up-to-2b-and-eight-targets Tristan Manalac All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. Thu, 04 Jun 2026 11:11:41 GMT https://www.biospace.com/deals/regeneron-deepens-relationship-with-cytomx-adding-up-to-2b-and-eight-targets https://www.biospace.com/deals/alnylam-hops-on-ai-train-with-up-to-2b-inceptive-partnership Tristan Manalac Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies. Thu, 04 Jun 2026 10:32:05 GMT https://www.biospace.com/deals/alnylam-hops-on-ai-train-with-up-to-2b-inceptive-partnership https://www.biospace.com/drug-development/rethinking-hair-loss-treatment Jennifer C. Smith-Parker BioSpace Insights In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients. Thu, 04 Jun 2026 08:21:24 GMT https://www.biospace.com/drug-development/rethinking-hair-loss-treatment https://www.biospace.com/career-advice/the-top-12-companies-hiring-in-biopharma-now Angela Gabriel Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you. Thu, 04 Jun 2026 07:00:00 GMT https://www.biospace.com/career-advice/the-top-12-companies-hiring-in-biopharma-now https://www.biospace.com/job-trends/how-long-is-too-long-weighing-and-accounting-for-employment-gaps Angela Gabriel It’s not unusual for it to take unemployed biopharma professionals awhile to land new jobs. Three experts discuss when employment gaps are an issue and how to explain them to prospective employers. Thu, 04 Jun 2026 07:00:00 GMT https://www.biospace.com/job-trends/how-long-is-too-long-weighing-and-accounting-for-employment-gaps https://www.biospace.com/fda/fda-hits-medline-with-warning-letter-over-long-running-contamination-problem Nick Paul Taylor FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products. Wed, 03 Jun 2026 18:08:38 GMT https://www.biospace.com/fda/fda-hits-medline-with-warning-letter-over-long-running-contamination-problem https://www.biospace.com/drug-development/ascos-biggest-winners-showcased-a-new-era-of-cancer-innovation Heather McKenzie Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso proved the PD-(L)1/VEGF mechanism and Eli Lilly showed that its in vivo CAR T bet is paying off. Wed, 03 Jun 2026 14:54:04 GMT https://www.biospace.com/drug-development/ascos-biggest-winners-showcased-a-new-era-of-cancer-innovation https://www.biospace.com/business/newlimit-snags-435m-after-seeing-age-reversal-in-human-liver-cells Gabrielle Masson NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. Wed, 03 Jun 2026 13:32:57 GMT https://www.biospace.com/business/newlimit-snags-435m-after-seeing-age-reversal-in-human-liver-cells https://www.biospace.com/drug-development/celcuity-slides-even-after-practice-changing-late-stage-breast-cancer-data Tristan Manalac Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday. Wed, 03 Jun 2026 11:45:10 GMT https://www.biospace.com/drug-development/celcuity-slides-even-after-practice-changing-late-stage-breast-cancer-data https://www.biospace.com/deals/travere-beefs-up-rare-kidney-disease-portfolio-with-up-to-1-1b-china-deal Tristan Manalac Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari. Wed, 03 Jun 2026 11:24:09 GMT https://www.biospace.com/deals/travere-beefs-up-rare-kidney-disease-portfolio-with-up-to-1-1b-china-deal https://www.biospace.com/fda/fda-policy-tracker-2026-priority-vouchers-questioned-prvs-return BioSpace Editorial Staff A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency. Wed, 03 Jun 2026 11:19:00 GMT https://www.biospace.com/fda/fda-policy-tracker-2026-priority-vouchers-questioned-prvs-return https://www.biospace.com/drug-development/legend-soars-on-best-in-class-best-in-disease-in-vivo-car-t-in-early-lymphoma-study Tristan Manalac All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer. Wed, 03 Jun 2026 11:12:39 GMT https://www.biospace.com/drug-development/legend-soars-on-best-in-class-best-in-disease-in-vivo-car-t-in-early-lymphoma-study https://www.biospace.com/deals/lilly-targets-kidney-disease-with-ascidians-rna-exon-editors-for-up-to-1-9b Tristan Manalac For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins. Wed, 03 Jun 2026 11:01:00 GMT https://www.biospace.com/deals/lilly-targets-kidney-disease-with-ascidians-rna-exon-editors-for-up-to-1-9b https://www.biospace.com/drug-development/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck Jef Akst Heather McKenzie Annalee Armstrong Gabrielle Masson Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting. Wed, 03 Jun 2026 10:33:01 GMT https://www.biospace.com/drug-development/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck https://www.biospace.com/business/facing-pressure-from-china-biospaces-nextgen-biotech-leaders-say-bring-it-on Annalee Armstrong From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night. Wed, 03 Jun 2026 04:18:00 GMT https://www.biospace.com/business/facing-pressure-from-china-biospaces-nextgen-biotech-leaders-say-bring-it-on https://www.biospace.com/business/no-longer-a-bargain-pool-chinese-biotechs-command-higher-premiums Leslie Zhen Liang Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals. Wed, 03 Jun 2026 04:03:00 GMT https://www.biospace.com/business/no-longer-a-bargain-pool-chinese-biotechs-command-higher-premiums